Unitedhealth Gp SEC Filings

UnitedHealth Group announced that senior leaders will participate in an interview at the UBS Global Healthcare Conference 2025. The session is scheduled for Monday, November 10, 2025, at 8:45 a.m. Eastern Time.

A live audio webcast will be accessible via the Investor Relations section of the company’s website. The disclosure is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Securities Exchange Act of 1934.

UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.

Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.

Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.

UnitedHealth Group (UNH) furnished an 8-K announcing its third quarter 2025 results. The company disclosed that it issued a press release detailing Q3 2025 performance, which is provided as Exhibit 99.1 and incorporated by reference.

The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act. The filing also includes the Cover Page Interactive Data File labeled as Exhibit 104.

Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported receipt of 289 deferred stock units as compensation on 10/01/2025. The units were issued at $0 and are immediately vested but must be retained until he leaves the Board. Following the grant, Mr. McNabb beneficially owns 14,341 shares (direct). The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), received 272 deferred stock units on 10/01/2025 as regular quarterly director compensation at a reported price of $0. The filing shows 9,810 shares beneficially owned following the transaction and an additional 6,033 shares held indirectly by trust. The form explains these deferred stock units are immediately vested but must be retained until the director leaves the board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.

UnitedHealth Group (UNH) director Kristen L. Gil received 162 shares of common stock as regular quarterly director compensation on 10/01/2025 at no cash price reported. After the grant, Ms. Gil directly beneficially owns 1,900 shares and indirectly owns 3,800 shares through a trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and notes the shares were granted as routine director compensation.

UnitedHealth Group (UNH) director Valerie C. Montgomery Rice, M.D. was granted 270 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units are immediately vested but must be held until she leaves the board. After the grant, her reported beneficial ownership of common stock is 6,897 shares, held directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

This Form 4 reports that Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), was granted 260 deferred stock units as director compensation on 10/01/2025. The units were granted at a $0 per-unit price and are described as immediately vested but required to be retained until the director leaves the Board. After the reported grant, the filing shows 1,516 shares (or equivalent units) beneficially owned by Mr. Baker. The form was signed by Faraz A. Choudhry, Attorney-in-Fact on 10/03/2025.

Michele J. Hooper, a director of UnitedHealth Group (UNH), was granted 162 deferred stock units on 10/01/2025 as regular quarterly director compensation. The grant was recorded at a reported price of $0 and increases her reported beneficial ownership to 40,877 shares following the transaction. The filing states the deferred stock units are immediately vested but must be retained until the director ends service on the Board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.